Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy

Medeot, Marta; Tiribelli, Mario; Sperotto, Alessandra; Geromin, Antonella; Fanin, Renato

doi:10.1002/ajh.23769

American J Hematol

2014

DOI: 10.1002/ajh.23769

|View full text |Cite

Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy

Marta Medeot

Mario Tiribelli

Alessandra Sperotto

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

2021

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies allowed the identification of several factors predicting overall outcome. Moreover, different scoring systems were established, which may be helpful in guiding clinical decision-making (14)(15)(16)(17). However, recent data on the long-term outcome of patients undergoing alloSCT with active AML are scarce (7,18,19).…”

mentioning

confidence: 99%

Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long‐term outcome

Hemmati

Terwey

et al. 2015

European J of Haematology

View full text Add to dashboard Cite

For patients with refractory acute myeloid leukemia (AML), allogeneic stem cell transplantation (alloSCT) represents the only curative approach. We here analyzed the long-term outcome of 131 consecutive patients with active AML, which was either primary refractory or unresponsive to salvage chemotherapy, transplanted at our center between 1997 and 2013. After a median follow-up of 48 months for the surviving patients, disease-free survival (DFS) at 5 yr post alloSCT was 26% (94% CI: 17-35). Relapses, most of which occurred within the first 2 yr from transplant, were the predominant cause of treatment failure affecting 48% (95%CI: 40-58) of patients, whereas non-relapse mortality was 26% (95%CI: 20-36) at 5 yr and thereafter. A marrow blast count ≥20% before alloSCT was an independent prognosticator associated with an inferior DFS (HR: 1.58, P = 0.027), whereas the development of chronic graft-versus-host disease (cGvHD) predicted an improved DFS (HR 0.21, P < 0.001) and a decreased relapse incidence (HR: 0.18, P = 0.026), respectively. These results indicate that alloSCT represents a curative treatment option in a substantial proportion of patients with refractory AML. A pretransplant blast count <20% before alloSCT and the development of cGvHD are the most important predictors of long-term disease control.

show abstract

mentioning

confidence: 99%

Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long‐term outcome

Hemmati

Terwey

et al. 2015

European J of Haematology

View full text Add to dashboard Cite

show abstract

Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis

Tachibana

Kanda

Ishizaki

et al. 2021

Transplantation and Cellular Therapy

View full text Add to dashboard Cite

Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis

et al. 2019

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy

Cited by 3 publications

References 7 publications

Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long‐term outcome

Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long‐term outcome

Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis

Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis

Contact Info

Product

Resources

About